Drug intelligence / Profile preview

HT-201

Development stage: Unknown
Lead developer: HepaThera
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

HT-201 is a recombinant fusion protein therapeutic being developed by HepaThera Biotech for the treatment of chronic hepatitis B (CHB). It is designed as a long-acting immunomodulator, specifically an Interleukin-21 (IL-21) based fusion protein, intended to restore the functionality of exhausted HBV-specific CD8+ T cells and promote B cell maturation. By revitalizing the host's immune response against the hepatitis B virus, HT-201 aims to achieve a functional cure, defined by the sustained loss of hepatitis B surface antigen (HBsAg). The drug is currently in Phase 1 clinical development, often positioned as part of a combination regimen to address the complex pathology of chronic viral infection.

Targets

IL21R (Interleukin-21 receptor)

Beyond the preview

Go deeper on HT-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HT-201.

Explore the full profile